|
|
Post by cedafuntennis on Jun 21, 2021 13:43:31 GMT -5
You are so wrong and I truly hope you do not have to discover on your own how wrong you are. The present medications, all of them, have been the same for the past 100 years or so and none work. Millions of patients lose limbs, have all sorts of severe medical problems, are not in range and gradually die from inside out. Just recently I met with a good friend who has T2 diabetes and suffered a mild cut to his leg and bleeding did not stop, developed an infection and had to go to the ER twice. All aggravated by his T2. Of course I told him about Afrezza and he told me that he heard of it but his Endo did not follow up at all. He will push more now, but this is the eternal issue. Endo's are old dogs who do not want learn new tricks, and the ones paying the ultimate price are the patients.
|
|
|
|
Post by uvula on Jun 21, 2021 13:52:01 GMT -5
This thread has taken so many twists and turns. I think at one point I was even debating myself. Afrezza is good. Covid vaccines are good. Tyvaso is good.
|
|
|
|
Post by cretin11 on Jun 21, 2021 14:07:16 GMT -5
baba you are right! Ironically one of my old pet peeves, but I lived up to my name this time. Or maybe, “if you can’t beat em, join em” and now I’m one of em 😂 Why join them in using a phrase that makes no sense? What's your rationale? Hmmm, that’s an incredibly insightful inquiry. I’d try to answer it except that I couldn’t care less about it. baba that one’s for you! 🤯💥👍🏼 |
|
|
|
Post by olderteampt on Jun 21, 2021 14:10:35 GMT -5
My last post on this topic:
Covid-19 has a 94.6 to 99.997 survival rate depending on your age. Diabetes has a 60% to 85% survival rate
|
|
|
|
Post by peppy on Jun 21, 2021 14:15:25 GMT -5
My last post on this topic: Covid-19 has a 94.6 to 99.997 survival rate depending on your age. Diabetes has a 60% to 85% survival rate can you plot that over time please. |
|
|
|
Post by mytakeonit on Jun 21, 2021 14:59:44 GMT -5
To save time ... when you die ... you end up in a plot.
But, that's mytakeonit
|
|
|
|
Post by falconquest on Jun 21, 2021 15:05:14 GMT -5
My last post on this topic: Covid-19 has a 94.6 to 99.997 survival rate depending on your age. Diabetes has a 60% to 85% survival rate Statistics are an interesting thing aren't they? A quick google search shows; the CDC reports that 79,535 deaths occur each year of complications of diabetes. How many people have died from covid over the last 18 months? |
|
|
|
Post by sayhey24 on Jun 21, 2021 15:39:38 GMT -5
What I think we have here is a $4B marketing failure but I also think we have a product years ahead of its time. The good news is UTHR has provided a life line to correct things and now we have a little time.
On an annual basis there are about 800k heart attacks in the U.S. and about 600k deaths from heart disease. The 600k deaths are clearly on par with Covid but I doubt Covid will have 600k deaths next year. I don't know how many of the 600k also had diabetes but they say if you have diabetes you have twice the likelihood of having a heart attack.
Of the non-diabetics having a heart attack how many where averaging above 140mg/dl for 2+ hours per day? Who knows but after Apple's BG sensor we may have a better clue.
Al saw afrezza as a T2 med. The fact is few expected to get T1 approval, at least initially. After 6+ years, its still not being marketed to the T2s. Can afrezza reduce heart disease by getting people under 140 when they are having 2+ hour excursions? I am pretty sure the answer is yes. Every time I see the SGLT2 commercials promoting heart healthy I cringe but I appreciate the basis of their claim.
Abbott is actively marketing the Libre with their new TV commercials to start the time in range discussion. Their current answer is don't eat the food you are about to eat. Why MNKD can't jump on that is a head scratcher but we do know Mike said that in 2021 T2s were not going to be a MNKD focus. Now that we are nearly 3Q2021 I sure hope Mike is starting his 2022 planning for the T2s.
If afrezza can be marketed as a heart disease slayer for the T2s then I think sales are off to the moon. I think Kendall had the nuggets of gold to show this through a combination of studies. If when the BG sensors hit the market in a couple of years can afrezza be positioned to be the solution to time out of range which leads to vascular degeneration leading to heart disease?
I think it can as SGLT2s have already paved the way but in the mean time Mike needs to start working some deals with Sens, or Abbott or Sayer and he needs to start proving out such a strategy. I see Sens has popped a bit over the last few weeks but I have no idea what their patient base is.
With the CGM and the remote monitoring - Sports issue of under dosing should be easily solved.
If we think Covid was a frenzy, what is going to happen when all these people start seeing their BG 180+ with the Apple watch? With the right marketing/knowledge they are going to lose their minds. There is only one solution to bringing down high BG in real time and that is human insulin. There is only one human insulin delivery system which mimics the pancreas and thats afrezza.
|
|
|
|
Post by nylefty on Jun 21, 2021 16:05:23 GMT -5
My last post on this topic: Covid-19 has a 94.6 to 99.997 survival rate depending on your age. Diabetes has a 60% to 85% survival rate Please clarify the diabetes "survival rate." I don't think that 60 to 85 percent live forever. |
|
|
|
Post by cretin11 on Jun 21, 2021 16:31:20 GMT -5
My last post on this topic: Covid-19 has a 94.6 to 99.997 survival rate depending on your age. Diabetes has a 60% to 85% survival rate Please clarify the diabetes "survival rate." I don't think that 60 to 85 percent live forever. We all have the same survival rate when we put it in those terms. Freddy Mercury had a song about that... |
|
|
|
Post by falconquest on Jun 21, 2021 18:03:59 GMT -5
What I think we have here is a $4B marketing failure but I also think we have a product years ahead of its time. The good news is UTHR has provided a life line to correct things and now we have a little time. On an annual basis there are about 800k heart attacks in the U.S. and about 600k deaths from heart disease. The 600k deaths are clearly on par with Covid but I doubt Covid will have 600k deaths next year. I don't know how many of the 600k also had diabetes but they say if you have diabetes you have twice the likelihood of having a heart attack. Of the non-diabetics having a heart attack how many where averaging above 140mg/dl for 2+ hours per day? Who knows but after Apple's BG sensor we may have a better clue. Al saw afrezza as a T2 med. The fact is few expected to get T1 approval, at least initially. After 6+ years, its still not being marketed to the T2s. Can afrezza reduce heart disease by getting people under 140 when they are having 2+ hour excursions? I am pretty sure the answer is yes. Every time I see the SGLT2 commercials promoting heart healthy I cringe but I appreciate the basis of their claim. Abbott is actively marketing the Libre with their new TV commercials to start the time in range discussion. Their current answer is don't eat the food you are about to eat. Why MNKD can't jump on that is a head scratcher but we do know Mike said that in 2021 T2s were not going to be a MNKD focus. Now that we are nearly 3Q2021 I sure hope Mike is starting his 2022 planning for the T2s. If afrezza can be marketed as a heart disease slayer for the T2s then I think sales are off to the moon. I think Kendall had the nuggets of gold to show this through a combination of studies. If when the BG sensors hit the market in a couple of years can afrezza be positioned to be the solution to time out of range which leads to vascular degeneration leading to heart disease? I think it can as SGLT2s have already paved the way but in the mean time Mike needs to start working some deals with Sens, or Abbott or Sayer and he needs to start proving out such a strategy. I see Sens has popped a bit over the last few weeks but I have no idea what their patient base is. With the CGM and the remote monitoring - Sports issue of under dosing should be easily solved. If we think Covid was a frenzy, what is going to happen when all these people start seeing their BG 180+ with the Apple watch? With the right marketing/knowledge they are going to lose their minds. There is only one solution to bringing down high BG in real time and that is human insulin. There is only one human insulin delivery system which mimics the pancreas and thats afrezza. I know this was discussed at the time and I don't want to dwell on it but there had to be a reason Kendall left. Was it because he had the very data that you mention but Castagna wouldn't listen to him? I lack confidence in Mike so we'll see what happens. |
|
|
|
Post by peppy on Jun 21, 2021 18:10:48 GMT -5
What I think we have here is a $4B marketing failure but I also think we have a product years ahead of its time. The good news is UTHR has provided a life line to correct things and now we have a little time. On an annual basis there are about 800k heart attacks in the U.S. and about 600k deaths from heart disease. The 600k deaths are clearly on par with Covid but I doubt Covid will have 600k deaths next year. I don't know how many of the 600k also had diabetes but they say if you have diabetes you have twice the likelihood of having a heart attack. Of the non-diabetics having a heart attack how many where averaging above 140mg/dl for 2+ hours per day? Who knows but after Apple's BG sensor we may have a better clue. Al saw afrezza as a T2 med. The fact is few expected to get T1 approval, at least initially. After 6+ years, its still not being marketed to the T2s. Can afrezza reduce heart disease by getting people under 140 when they are having 2+ hour excursions? I am pretty sure the answer is yes. Every time I see the SGLT2 commercials promoting heart healthy I cringe but I appreciate the basis of their claim. Abbott is actively marketing the Libre with their new TV commercials to start the time in range discussion. Their current answer is don't eat the food you are about to eat. Why MNKD can't jump on that is a head scratcher but we do know Mike said that in 2021 T2s were not going to be a MNKD focus. Now that we are nearly 3Q2021 I sure hope Mike is starting his 2022 planning for the T2s. If afrezza can be marketed as a heart disease slayer for the T2s then I think sales are off to the moon. I think Kendall had the nuggets of gold to show this through a combination of studies. If when the BG sensors hit the market in a couple of years can afrezza be positioned to be the solution to time out of range which leads to vascular degeneration leading to heart disease? I think it can as SGLT2s have already paved the way but in the mean time Mike needs to start working some deals with Sens, or Abbott or Sayer and he needs to start proving out such a strategy. I see Sens has popped a bit over the last few weeks but I have no idea what their patient base is. With the CGM and the remote monitoring - Sports issue of under dosing should be easily solved. If we think Covid was a frenzy, what is going to happen when all these people start seeing their BG 180+ with the Apple watch? With the right marketing/knowledge they are going to lose their minds. There is only one solution to bringing down high BG in real time and that is human insulin. There is only one human insulin delivery system which mimics the pancreas and thats afrezza. I know this was discussed at the time and I don't want to dwell on it but there had to be a reason Kendall left. Was it because he had the very data that you mention but Castagna wouldn't listen to him? I lack confidence in Mike so we'll see what happens. I think it was because the ADA wouldn't listen to him. Standards of Care. |
|
|
|
Post by georgethenight2 on Jun 21, 2021 18:33:36 GMT -5
Positive news for MannKind this week. Afrezza scripts jumping 2-3X next year not gonna happen. The leveling off is Real and it’s not because of coverage. See my prior comments 2-3 yrs ago about pricing differences in mealtime insulin. It’s too late for MannKind to drop the price of Afrezza 80% to still only be 3X the cost. The sales force expenditure is nothing but a money drain at this point for MK. Zero growth in 2 yrs. The Afrezza sales force is at least 30Million a year and that’s probably light. Volume would stay the same if the sales force was gone tomorrow. However MC, Medtronic dude, HR guy Stu (making $500k per year) and MB couldn’t justify their jobs. Had to comment cause I heard another person talk about 2 to 3 times growth w/Afrezza next year. But Stu and LinkedIn comments make everyone feel good. 500k. Jesus. And his damn options, multimillionaire for sure. Oh well. |
|
|
|
Post by mcbone on Jun 21, 2021 18:37:45 GMT -5
Kendall came from a strong company (Lilly) where he had funding to do the studies he needed to do. Then he came to MNKD at a time when it was barely solvent and no money to do anything -- no studies, no trials, nothing. Just sit and wait was the MC strategy, and still is, except for the UTHR deal. Maybe Kendall became disillusioned after a couple of years of not being able to use his talents because MNKD couldn't and wouldn't pay to get anything done.
|
|
|
|
Post by buyitonsale on Jun 21, 2021 18:42:21 GMT -5
MNKD will continue to develop (pediatrics) and market Afrezza (with more resources now than ever before).
Because it is a better insulin that can provide a better outcome (unmet need).
Diabetics that want to take control of their blood glucose / time in range, and improve their health will adapt it.
And CGM adoption is also a huge x factor, who would want to use a slow and painful insulin...
Bottom line.
|
|
